Advertisement
News
Subscribe to MDT Magazine News

CardioGenics Featured on Canada's Business News Network

August 18, 2010 8:33 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, Aug. 18 /- Dr. Yahia Gawad, CEO of CardioGenics Inc. (OTC Bulletin Board: CGNH ), developer of the ultra-sensitive QL Care™ Point-Of-Care (POC) analyzer and products for the immunoassay segment of the In-Vitro Diagnostics market, took part in an interview on...

TOPICS:

AirPal Expands Line of Air-Activated Transfer Pads to Include Multi-Purpose Patient Positioning Functionality

August 18, 2010 8:32 am | by Bio-Medicine.Org | Comments

NORTH WALES, Pa., Aug. 18 /- AirPal ®, a leading innovator and supplier of lateral air transfer and positioning technology, has announced the expansion of its line of air-activated transfer pads to incorporate multi-purpose patient positioning functionality. "This announcement marks...

TOPICS:

Nominations Open for 2011 Pezcoller Foundation-AACR International Award for Cancer Research

August 18, 2010 8:32 am | by AACR | Comments

PHILADELPHIA - The American Association for Cancer Research is currently accepting nominations for the prestigious Pezcoller Foundation-AACR International Award for Cancer Research.

TOPICS:
Advertisement

Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in...

August 18, 2010 4:36 am | by Bio-Medicine.Org | Comments

FREMONT, Calif., Aug. 18 /- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor...

TOPICS:

Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting

August 18, 2010 4:36 am | by Bio-Medicine.Org | Comments

KIRKLAND, Wash., Aug. 18 /- Cardiac Dimensions, an early stage company focused on the development of minimally invasive devices for the treatment of mitral valve disease and congestive heart failure, announced today that the 12-month follow-up results from the TITAN™ trial of the...

TOPICS:

Research could change course of treatment for cancer that spreads to bones

August 18, 2010 4:35 am | by EurekAlert | Comments

(Southern Methodist University) New research holds promise for people whose cancer has spread to their bones. A common treatment for such patients is radiosurgery ? even though little is known about its impact on bone strength, says Edmond Richer at Southern Methodist University, Dallas....

TOPICS:

Out-of-the-ordinary life science ideas offer potential business success

August 17, 2010 10:32 pm | by Mass High Tech: The Journal of New England Technology | Comments

Turning a “cool idea” into the “next big thing” takes perserverence, an unwavering commitment to a vision, and usually, in the life sciences, a boatload of cash. Local entrepreneurs say the challenge lies in convincing funders (or customers) of the value proposition of the product.

TOPICS:

Think of the global good

August 17, 2010 10:31 pm | by Mass High Tech: The Journal of New England Technology | Comments

In this issue we set out to address a core question: How do different types of life sciences companies make money? Yet, there's another question that we also felt it was important to address: Can a company work for the public good even when there is little or no hope of turning a profit?

TOPICS:
Advertisement

VCs discuss potential life science investment pitfalls

August 17, 2010 9:33 pm | by Mass High Tech: The Journal of New England Technology | Comments

Two Boston VCs known for not being shy of risk, SV Life Sciences' James Garvey and PureTech Ventures' Daphne Zohar, told Mass High Tech where they're applying a higher level of scrutiny before investing and what life science categories they're avoiding like the plague.

TOPICS:

Regenerative medicine gets on a profitable roll

August 17, 2010 9:32 pm | by Mass High Tech: The Journal of New England Technology | Comments

After getting off to a false start in the 1990s, the field of regenerative medicine has been reborn over the past decade. Now, several New England companies are showing that regenerative medicine - generally defined as therapy that uses living cells to repair the body - is more than just...

TOPICS:

Cardica signs contract deal with Intuitive

August 17, 2010 2:45 pm | by The Associated Press | Comments

Surgical systems maker Cardica Inc. said Tuesday it entered a licensing deal worth $12 million upfront with Intuitive Surgical Inc.Under the deal, Intuitive will get a worldwide, exclusive license to Cardica's intellectual property, which relates to tissue cutting, stapling and clip appliers,...

TOPICS:

Cardica 4Q loss narrows on smaller sales force

August 17, 2010 2:45 pm | by The Associated Press | Comments

Surgical systems maker Cardica Inc. said Tuesday its fiscal fourth quarter loss narrowed on lower costs following cuts to its sales force.The company lost $3.1 million, or 13 cents per share, compared with a loss of $3.5 million, or 22 cents per share, during the same period a year prior....

Prospect Medical turns fiscal 3Q profit of $2.8 M

August 17, 2010 12:45 pm | by The Associated Press | Comments

Prospect Medical Holdings Inc., which has agreed to be acquired by a private equity firm, said Tuesday it turned a profit in its fiscal third quarter as revenue edged up 2 percent.The Los Angeles company has five hospitals in Southern California and provides health care management services to...

BridgeHead Software Appoints New EMEA Sales Director to Build on Company & #8217;s Presence in Private and Public Sector European Healthcare

August 17, 2010 9:33 am | by RealWire | Comments

Tony Tomkys comes to BridgeHead Software from CommVault, where he was Business Director for Public SectorAshtead, UK - Tuesday August 17 2010 - BridgeHead Software, the Healthcare Storage Virtualization (HSV) company, today announced the appointment of Tony Tomkys to head up their sales...

TOPICS:

BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU

August 17, 2010 9:33 am | by Bio-Medicine.Org | Comments

NOVATO, Calif., Aug. 17 /- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading